Covidien, BioSynthema Sign Exclusive Agreements

October 18, 2007 - Covidien Ltd. and BioSynthema Inc. recently announced the signing of agreements to develop and commercialize a nuclear medicine therapy for neuroendocrine cancer patients.
Under the terms of an exclusive license agreement, BioSynthema will gain access to specific Covidien proprietary peptide technology. The license will enable BioSynthema to use this technology in conjunction with its own technology and proprietary clinical research to further develop a new targeted radionuclide therapy product.
Under the terms of a separate agreement, Covidien will have exclusive marketing rights to the resulting cancer therapy technology.
For more information: www.biosynthema.com

Related Content

Paige, a provider of end-to-end digital pathology solutions and clinical AI, has announced a collaboration with Microsoft to build what they refer to as the world’s largest image-based AI models for digital pathology and oncology.

News | Artificial Intelligence

Microsoft and Paige Announce Collaboration on Image-based AI Model in Fight Against Cancer

September 7, 2023 — Paige, a provider of end-to-end digital pathology solutions and clinical AI, has announced a ...

September 07, 2023

News | Radiology Business

TAE Life Sciences Promotes Rob Hill to CEO

July 27, 2023 — Privately-held biotech company TAE Life Sciences has announced that its board of directors has appointed ...

July 27, 2023

News | Interventional Radiology

Varian Purchasing Embolic Bead Assets from Boston Scientific

Varian announced it has signed an asset purchase agreement to acquire the Boston Scientific portfolio of drug-loadable microsphere and bland embolic bead products for treating arteriovenous malformations and hypervascular tumors. When completed, this acquisition, in combination with the recent acquisitions of Endocare and Alicon, will expand Varian's portfolio of multidisciplinary integrated cancer care solutions.

July 03, 2019

Technology | Focused Ultrasound Therapy

FDA Approves Exablate Neuro for Tremor-Dominant Parkinson's Treatment

Insightec announced that the U.S. Food and Drug Administration (FDA) has approved an expansion of the indication of Exablate Neuro to include the treatment of patients with tremor-dominant Parkinson's disease (PD).

December 21, 2018

Videos | Radiation Oncology

VIDEO: Personalizing Radiotherapy Using Genomic Markers of Radiosensitivity

Genomics can be used to assess a patient's radiosensitivity, which can be used to increase or decrease the radiation ...

November 06, 2018

News | Radiation Dose Management

AngioDynamics to Acquire RadiaDyne to Expand Oncology Portfolio

AngioDynamics Inc. announced an agreement to acquire RadiaDyne, a privately held medical diagnostic and device company that designs and develops patient dose monitoring technology to improve cancer treatment outcomes.

September 24, 2018